Online inquiry

IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15196MR)

This product GTTS-WQ15196MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ15196MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8917MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ15350MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ12841MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ4779MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ2761MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ2032MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ3797MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ10190MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LDP-02
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW